Delayed Graft Function Clinical Trial
Official title:
Clinical Utility of Biomarkers of Aging as Predictors of Kidney Graft Function in Extended Criteria Organ Recipients
The primary purpose of this study is to measure the correlation between baseline expression of aging biomarkers, SenesceTest in blood of organ donor and renal graft function. This pilot study will study patients who are undergoing renal transplantation with organs from extended criteria donors, standard criteria donors or donation after cardiac death and compare ability of SenesceTest to predict renal graft function immediately after the transplant and at 1 year followup.
Presently, donated organs are ranked amongst each other based on a formula for Kidney Donor
Patient Index (KDPI; a variation of Donor Risk index) 8 which includes donor demographics
and clinical history but no molecular markers of kidney function other than serum
creatinine. Using KDPI assessment, nearly all ECD kidneys fall into the high-risk category.
And while ECD kidneys are associated with higher risk of graft failure, studies note a wide
variability in ECD organ quality and the associated graft survival (half-life graft survival
4.5-7.9 years), suggesting that current models of assessing organ quality are inadequate.
Furthermore, prior to even being assigned a KDPI, over 37% of all kidneys and over 50% of
ECD kidneys are discarded based on biopsy findings. However, recent studies called into
question the reliance on procurement kidney biopsy reports in making acceptance decisions by
demonstrating significant overlap in the biopsy findings between discarded and transplanted
kidneys. The use of ECD kidneys is becoming more widespread and, according to a recent
report, 70% adults >65yo and 50% adults between 50 and 64 yo are willing to accept an ECD
kidney. Therefore, new methodology for assessment of graft viability would increase
transplantation rates particularly for organs from older or expanded criteria donors,
shorten patient's time on wait list (currently 45 months average 50) and improve their
outcomes by taking them off dialysis sooner.
Here, we propose a new approach—using molecular age markers (collectively referred to as
SenesceTest) to predict kidney graft function.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02312115 -
Delayed Renal Allograft Function and Furosemide Treatment
|
Phase 2 | |
Completed |
NCT02134314 -
C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI
|
Phase 1/Phase 2 | |
Completed |
NCT02346968 -
Evaluation of CAF22 After Renal Transplantation
|
||
Completed |
NCT01794663 -
Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function
|
Phase 2 | |
Completed |
NCT00298181 -
YSPSL for Prevention of Delayed Graft Function Part A
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05166460 -
Novel Cooling Device for the Elimination of Warm Ischemia During Renal Transplantation
|
N/A | |
Recruiting |
NCT03071536 -
Furosemide Stress Test Predicting Early Graft Function in Kidney Transplantation
|
N/A | |
Not yet recruiting |
NCT05513807 -
Graft Acute Kidney Injury: Vitamin B3 to Facilitate Renal Recovery In the Early Life of a Transplant
|
Phase 3 | |
Recruiting |
NCT04005469 -
Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During Kidney Transplantation
|
Phase 1/Phase 2 | |
Completed |
NCT01848249 -
Deceased Donor Biomarkers and Recipient Outcomes
|
||
Active, not recruiting |
NCT02474667 -
Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney
|
Phase 3 | |
No longer available |
NCT02026934 -
CliniMACS® CD34+ Reagent System for Expanded Access Use
|
N/A | |
Terminated |
NCT00217152 -
A Kidney Transplant Study to Look at the Effects of Taking Fixed Doses of CellCept Versus Taking Doses of CellCept Based on the Concentration of CellCept in the Blood When Taking Full or Reduced Dose Calcineurin Inhibitors
|
Phase 4 | |
Recruiting |
NCT05430620 -
Intermittent Versus Continuous Surface O2 During HMP of DCD Kidneys
|
Phase 3 | |
Completed |
NCT03864926 -
Envarsus in Delayed Graft Function (E-DGF)
|
Phase 4 | |
Recruiting |
NCT06367205 -
Norepinephrine Infusion Combined With Goal-directed Fluid Therapy in Patients Undergoing Kidney Transplantations
|
N/A | |
Completed |
NCT02610296 -
QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant
|
Phase 3 | |
Active, not recruiting |
NCT02568696 -
Intra-graft Coagulation Events in Clinical Renal Transplantation and Delayed Graft Function
|
||
Recruiting |
NCT01837043 -
Early Conversion From CNI to Belatacept in Renal Transplant Recipients With Delayed and Slow Graft Function
|
Phase 2 | |
Terminated |
NCT01878786 -
A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys
|
Phase 2/Phase 3 |